Sell of the Derm Division

anonymous

Guest
It was a bad bet made at the C level that Sotyktu would sell better than Otezla. Like it or not that was a bad bet. To prop up the stock BMY should spin off the derm division and reallocate assets to molecules that generate revenue. Sotyktu will suck BMY dry of resources. It's time to face the facts. If you are in dermatology, I'd be looking for other opportunities.
 




It was a bad bet made at the C level that Sotyktu would sell better than Otezla. Like it or not that was a bad bet. To prop up the stock BMY should spin off the derm division and reallocate assets to molecules that generate revenue. Sotyktu will suck BMY dry of resources. It's time to face the facts. If you are in dermatology, I'd be looking for other opportunities.

Yours truly, Amgen
 




Nah I think he/she is right. I’ve started to look but do I want to take a pay cut? That’s what I’m dealing with now. BMS pays base salaries so high that no other company can come close.